APPLIED BIOCODE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.6 TWD | -1.01% |
|
-3.21% | -22.53% |
| Apr. 15 | Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only | CI |
| Mar. 21 | Applied BioCode Announces CEO Changes | CI |
| Sales 2024 * | 430M 13.2M | Sales 2025 * | - | Capitalization | 1.6B 49.2M |
|---|---|---|---|---|---|
| Net income 2024 * | -145M -4.45M | Net income 2025 * | - | EV / Sales 2024 * | 3.73 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-11
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.01% | ||
| 1 week | -3.21% | ||
| Current month | -8.84% | ||
| 1 month | -9.47% | ||
| 3 months | -14.60% | ||
| 6 months | -7.33% | ||
| Current year | -22.53% |
1 week
19.30
20.10
1 month
19.3022.00
Current year
19.3026.85
1 year
19.3028.40
3 years
19.3060.70
5 years
19.30182.50
10 years
19.30182.50
| Managers | Title | Age | Since |
|---|---|---|---|
Zonh Zen Ho
CEO | Chief Executive Officer | - | 07-12-31 |
Liang Kai Huang
DFI | Director of Finance/CFO | - | 18-01-31 |
Cassandra Ingles
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Lee
CHM | Chairman | 73 | 16-06-29 |
Benjamin Jen
BRD | Director/Board Member | 58 | 16-09-28 |
Wen Ching Tsai
BRD | Director/Board Member | - | 16-09-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 19.6 | -1.01% | 69,165 |
| 24-04-24 | 19.8 | +0.25% | 59,085 |
| 24-04-23 | 19.75 | -0.75% | 86,781 |
| 24-04-22 | 19.9 | -1.00% | 46,550 |
| 24-04-19 | 20.1 | -0.74% | 119,028 |
End-of-day quote Taiwan S.E., April 24, 2024
More quotes
Applied BioCode Corp is a is a Taiwan-based company mainly engaged in the provision of automated multiple detection platforms, various application development of detection platforms, as well as the research, development and sale of infectious disease diagnostic reagents. The Company's main products include digital barcode magnetic beads (BMB), optical analyzers, in vitro diagnostic reagents and others. The Company sells in the United States, Europe and Asia markets.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.6
TWD
Average target price
22
TWD
Spread / Average Target
+12.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.53% | 49.16M | |
| -20.53% | 10.67B | |
| +41.94% | 3.22B | |
| -36.56% | 2.09B | |
| -18.92% | 2.04B | |
| -29.19% | 1.46B | |
| +15.73% | 1B | |
| -4.37% | 734M | |
| -37.00% | 391M | |
| -46.73% | 379M |
- Stock Market
- Equities
- 6598 Stock
